Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H7O3.Na |
| Molecular Weight | 198.1505 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC1=CC(=O)OC2=C1C=CC([O-])=C2
InChI
InChIKey=JGMQHDNPUCPRQE-UHFFFAOYSA-M
InChI=1S/C10H8O3.Na/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9;/h2-5,11H,1H3;/q;+1/p-1
| Molecular Formula | C10H7O3 |
| Molecular Weight | 175.1608 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25852691
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25852691
Hymecromone (4-methylumbelliferone) is already approved drug in Europe and Asia where it is used to treat biliary spasm. It is used as choleretic and antispasmodic drugs and as a standard for the fluorometric determination of enzyme activity. The concomitant administration of Hymecromone with products, containing metoclopramide, leads to mutual decrease of their action. Due to a danger of diarrhea with subsequent hypokalemia, Hymecromone should be applied with caution to patients on cardiac glycosides therapy (in these cases the sensitivity to them is increased). Hymecromone can be administered simultaneously with otherspasmolytics and analgesics. Very rare allergic reactions, itching, erythema, rashes; diarrhea which normally disappears by reduction of dose or discontinuance of therapy.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| New lanthanide complexes of 4-methyl-7-hydroxycoumarin and their pharmacological activity. | 2001 Apr |
|
| Extracellular enzyme activities during slow sand filtration in a water recharge plant. | 2001 Jul |
|
| Translocon pores in the endoplasmic reticulum are permeable to a neutral, polar molecule. | 2001 Jun 22 |
|
| A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). | 2001 Nov |
|
| High beta-galactosidase and ganglioside GM1 levels in the human parotid gland. | 2001 Nov |
|
| A fluorogenic assay using pressure-driven flow on a microchip. | 2001 Oct |
|
| New metal complexes of 4-methyl-7-hydroxycoumarin sodium salt and their pharmacological activity. | 2001 Sep |
|
| Optimisation of an enzymatic method for beta-galactosidase. | 2002 Dec |
|
| The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6. | 2002 May 20 |
|
| Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. | 2002 Nov |
|
| A colorimetric and fluorometric microplate assay for the detection of microcystin-LR in drinking water without preconcentration. | 2002 Nov |
|
| Inhibition of hyaluronan synthesis in Streptococcus equi FM100 by 4-methylumbelliferone. | 2002 Oct |
|
| Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. | 2002 Oct |
|
| A 45-kDa midgut glycoprotein from Anopheles albimanus mosquito mediates the killing of trypanosomes. | 2002 Sep |
|
| Aryl sulfatase from Naja nigricolis venom: characterization and possible contribution in the pathology of snake poisoning. | 2003 |
|
| Inhibition of rat liver sulfotransferases SULT1A1 and SULT2A1 and glucuronosyltransferase by dietary flavonoids. | 2003 Dec |
|
| Microtiter plate cellular assay for human steroid sulfatase with fluorescence readout. | 2003 Jul 15 |
|
| Glucuronidation of 4-methylumbelliferone and 4-hydroxybiphenyl and in vitro induction of UDP-glucuronosyltransferase 2B12-mRNA in precision-cut rat liver slices. | 2003 Jun |
|
| Physicochemical and saccharide-binding studies on the galactose-specific seed lectin from Trichosanthes cucumerina. | 2003 May 1 |
|
| A nonradioactive 96-well plate assay for screening of trans-sialidase activity. | 2003 Nov 15 |
|
| Cloning and expression of alpha-D-glucosidase and N-acetyl-beta-glucosaminidase from the periodontal pathogen, Tannerella forsythensis (Bacteroides forsythus). | 2003 Oct |
|
| Mechanism of the hydrolysis of 4-methylumbelliferyl-beta-D-glucoside by germinating and outgrowing spores of Bacillus species. | 2004 |
|
| Molecular characterization of membrane type and ganglioside-specific sialidase (Neu3) expressed in E. coli. | 2004 Apr 30 |
|
| Risk factors for periodontitis in HIV patients. | 2004 Jun |
|
| Stability of the complexes of some lanthanides with coumarin derivatives. I. Cerium(III)-4-methyl-7-hydroxycoumarin. | 2004 Mar |
|
| Effects of dietary anticarcinogens and nonsteroidal anti-inflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases. | 2004 Mar-Apr |
|
| A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. | 2004 Sep |
Sample Use Guides
1 tablet 3 times daily during basic meals. The tablets are administered unchewed with a liquid.
Route of Administration:
Oral
4-Methylumbelliferone (4-MU/HYMECROMONE) inhibits hyaluronan synthesis and retards cancer spreading in experimental animals through mechanisms not fully understood. These mechanisms were studied in A2058 melanoma cells, MCF-7 and MDA-MB-361 breast, SKOV-3 ovarian and UT-SCC118 squamous carcinoma cells by analysing hyaluronan synthesis, UDP-glucuronic acid (UDP-GlcUA) content, and hyaluronan synthase (HAS) mRNA levels. The maximal inhibition in hyaluronan synthesis ranged 22-80% in the cell lines tested. Active glucuronidation of 4-MU produced large quantities of 4-MU-glucuronide, depleting the cellular UDP-GlcUA pool. The maximal reduction varied between 38 and 95%. 4-MU also downregulated HAS mRNA levels: HAS3 was 84-60% lower in MDA-MB-361, A2058 and SKOV-3 cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:07:07 GMT 2023
by
admin
on
Fri Dec 15 15:07:07 GMT 2023
|
| Record UNII |
86UG9WCF3N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
227-790-1
Created by
admin on Fri Dec 15 15:07:07 GMT 2023 , Edited by admin on Fri Dec 15 15:07:07 GMT 2023
|
PRIMARY | |||
|
3364573
Created by
admin on Fri Dec 15 15:07:07 GMT 2023 , Edited by admin on Fri Dec 15 15:07:07 GMT 2023
|
PRIMARY | |||
|
86UG9WCF3N
Created by
admin on Fri Dec 15 15:07:07 GMT 2023 , Edited by admin on Fri Dec 15 15:07:07 GMT 2023
|
PRIMARY | |||
|
5980-33-6
Created by
admin on Fri Dec 15 15:07:07 GMT 2023 , Edited by admin on Fri Dec 15 15:07:07 GMT 2023
|
PRIMARY | |||
|
DTXSID90208538
Created by
admin on Fri Dec 15 15:07:07 GMT 2023 , Edited by admin on Fri Dec 15 15:07:07 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |